Novartis India Ltd (NOVARTIND) — FY26 Annual Report | 2 September 2026

· BSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
70.68% stake sale to private equity firms triggers new director appointments and AGM regularization
🔄 What Changed
New directors appointed post-acquisition; ESOP scheme approved; name change proposed; no dividend recommended
🔮 What's Next
AGM scheduled for September 24, 2026, to approve director appointments and remuneration
💡 Investor Takeaway
Shareholder approval required for new directors and name change; no dividend signals cash retention for strategic use

Novartis India Ltd's 2025-26 Annual Report details the completion of a 70.68% stake sale to WaveRise, ChrysCapital Fund X, and Two Infinity Partners on July 29, 2026, ending Novartis AG's promoter status. The AGM on September 24, 2026, will regularize new director appointments including Ashok Bhatia, Kshitij Sheth, Dr. Jagriti Gupta, Ramesh Ramadurai, and Shashank Sinha. The report outlines remuneration for directors, an ESOP scheme for 1.67 million shares, and a proposed name change to Evonile Pharma Limited. Financials show revenue of ₹3,543.3 million and PAT of ₹931.8 million, with no dividend recommended due to pending share transactions.

📄 View Original Announcement (PDF)

About Novartis India Ltd (NOVARTIND)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹5,908.88 Cr P/E: 60.4 ROE: 11.9% ROCE: 16.7%

View full NOVARTIND stock details →

📡 Get AI alerts when NOVARTIND files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track NOVARTIND — Free

📊 More NOVARTIND filings

See all NOVARTIND filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when NOVARTIND files new disclosures

Track NOVARTIND filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track NOVARTIND — Free

Free account · 2 AI queries/day